Disease characteristics | CML Patients (n = 150) | Imatinib 400-mg OD dose group (n = 59) | Imatinib 600-mg OD dose group (n = 91) |
---|---|---|---|
Splenomegaly, n (%) | |||
 No | 57 (38) | 27 (47) | 30 (53) |
 Yes | 93 (62) | 32 (34) | 61 (66) |
Hepatomegaly, n (%) | |||
 No | 113 (75) | 44 (39) | 69 (61) |
 Yes | 37 (25) | 15 (40.5) | 22(59.5) |